Bertrand Routy

Bertrand Routy led the clinical trial demonstrating that CBM588 (Clostridium butyricum) combined with nivolumab-ipilimumab significantly improved progression-free survival in metastatic renal cell carcinoma, providing the first randomized evidence for microbiome modulation as cancer therapy. His epidemiological studies quantified the negative impact of antibiotic use on immunotherapy outcomes, leading to antibiotic stewardship guidelines in oncology. His work on microbiome profiling as a predictive biomarker for immunotherapy selection has advanced the clinical implementation of microbiome-guided therapy.